Topic: mergers and acquisitions
BMS CEO Giovanni Caforio's pay dipped slightly to $18.8 million last year, as his incentives were tied to the successful integration of Celgene.
Mylan and Pfizer have already postponed the close of their generic merger amid COVID-19 concerns. Now the pair is hoping to speed up EU review.
With Pfizer shipping out two directors to lead its Upjohn merger with Mylan, the drugmaker has picked up two board members to take their place.
Waiting expectantly for U.S. approval of their $63 billion merger, AbbVie and Allergan received a final nod from the EU after offloading two assets.
Viatris, the merger of Mylan and Pfizer's Upjohn, has fleshed out its board and C-suite with a raft of Pfizer and Mylan veterans.
With CGRPs on the rise, Allergan's Botox is holding onto neurologist support in migraine patients. That preference could be a big win for AbbVie.
Endo's Paul Campanelli is officially out as CEO. With his CFO's move to the helm and an M&A specialist joining the board, are deals on the way?
Pfizer's Upjohn has reached a deal to exclusively supply generic Viagra to telehealth provider Roman as the company prepares to merge with Mylan.
Independent pharma and healthcare agency W2O Group bought 21GRAMS today in a deal that expands the parent group’s creative capabilities.
After months of regulatory scrutiny, the EU has given AbbVie and Allergan's $63 billion merger its first go-ahead in anticipation of an FTC decision.